Accelerated Approval Should Be Less 'Wide Open,' Califf Says
FDA should write more about its interpretation of regs and apply it more consistently across divisions, commissioner says.
You may also be interested in...
Emails reveal company wanted timelines and approval commitments from FDA toward the end of the eteplirsen review, saying it might not be able to continue studies; at the same time, Sarepta was telling investors it had 12 months of cash on hand.
Investor compares the development construct to homeopathic medicine.
FDA commissioner offers new details about why he left final decision on Sarepta's controversial Duchenne muscular dystrophy drug to FDA's expert bureaucrats.